But Illumina's pending acquisition of Pacific Biosciences of California (NASDAQ: PACB) should shore up its weakness in this area. Wall Street's more conservative take on the drug has it generating around $545 million at peak, but more optimistic estimates put HTX-011's commercial opportunity into megablockbuster territory at roughly $2 billion a year in sales. Same-store sales rose by a better-than-expected 3.8%, with brand-name drug inflation, especially with regard to Medicare Part D, boosting results, and the company reaping the rewards of its first full quarter of the Aetna integration.